Oncology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Promoter hypermethylation mediates downregulation of thiamine receptor slc19a3 in gastric cancer
Tumor Biology, 10/12/09

Liua X et al. – SLC19A3 was epigenetically downregulated in gastric cancer. Methylation of SLC19A3 promoter could be a novel biomarker for early gastric cancer development

Methods

Promoter hypermethylation used to define novel TSGs and identify biomarkers for cancer diagnosis
SLC19A3 expression downregulated in gastric cancer cell lines (71%, 5/7) and restored after pharmacological demethylation

Results

SLC19A3 (solute carrier family 19, member 3) found to be such a biomarker
Hypermethylation of SLC19A3 promoter detected in gastric cancer cell lines (57%, 4/7), primary gastric carcinoma tissues (51%, 52/101) and precancerous lesion (intestinal metaplasia) tissues (32%, 8/25)
Exogenous SLC19A3 expression caused growth inhibition of gastric cancer cells

<< Previous
New lesions detected by single nucleotide polymorphism...

Next >>
Dose-Ranging Study of Metronomic Oral Vinorelbine in Patients...